Scholar Rock (NASDAQ:SRRK) Issues Quarterly Earnings Results

Key Points

• Scholar Rock missed earnings estimates slightly, reporting quarterly EPS of ($0.83) versus the expected ($0.82). Results were also worse than the $0.67 loss per share posted in the same quarter last year.
• The FDA accepted the company’s BLA for apitegromab to treat spinal muscular atrophy and set a PDUFA action date of September 30, 2026. This gives the biotech a clear regulatory catalyst ahead.
• There is some regulatory and manufacturing uncertainty because the FDA’s unannounced re-inspection of the Catalent fill-finish site could take up to 90 days to classify. Scholar Rock says it has added a second U.S. fill-finish facility and expects ample commercial supply in early Q3.

Scholar Rock (NASDAQ:SRRK - Get Free Report) issued its quarterly earnings data on Thursday. The company reported ($0.83) EPS for the quarter, missing the consensus estimate of ($0.82) by ($0.01), FiscalAI reports. During the same period last year, the company posted ($0.67) EPS.

Here are the key takeaways from Scholar Rock's conference call:

• FDA accepted Scholar Rock's BLA for apitegromab to treat children and adults with SMA and assigned a PDUFA action date of September 30, 2026, creating a clear potential approval catalyst.
• The FDA completed an unannounced re‑inspection of the Catalent, Indiana fill–finish site and now has up to 90 days to classify the facility, leaving regulatory timing uncertainty that could affect approval pacing.
• Scholar Rock included a second U.S. fill–finish facility in the resubmitted BLA and reports that all required drug product from that site has been filed, with ample commercial supply expected in early Q3 ahead of the PDUFA date.
• The company exited Q1 with $480 million in cash and marketable securities, drew an additional $100 million from its debt facility and $98 million from ATM proceeds, and retains options (additional draw and PRV monetization) to further strengthen the balance sheet.
• Pipeline momentum continues with enrollment in the OPAL infant/toddler SMA study, a planned mid‑year start of the phase II FORGE trial in FSHD, encouraging subcutaneous apitegromab phase I data, and ongoing phase I dosing of SRK‑439.

Scholar Rock Stock Up 4.2%

Shares of Scholar Rock stock traded up $1.94 during trading on Friday, hitting $48.39. The company's stock had a trading volume of 1,049,039 shares, compared to its average volume of 1,331,426. The company has a debt-to-equity ratio of 0.41, a quick ratio of 6.95 and a current ratio of 6.95. The company has a fifty day simple moving average of $46.15 and a two-hundred day simple moving average of $43.00. The company has a market capitalization of $5.77 billion, a PE ratio of -14.11 and a beta of 0.70. Scholar Rock has a 52 week low of $27.07 and a 52 week high of $51.63.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. BMO Capital Markets upped their price objective on shares of Scholar Rock from $50.00 to $70.00 and gave the stock an "outperform" rating in a report on Wednesday, March 4th. Canaccord Genuity Group assumed coverage on shares of Scholar Rock in a report on Monday, April 20th. They issued a "buy" rating and a $62.00 price objective for the company. Raymond James Financial restated a "strong-buy" rating on shares of Scholar Rock in a report on Tuesday, March 3rd. Citigroup upped their price objective on shares of Scholar Rock from $55.00 to $58.00 and gave the stock a "buy" rating in a report on Wednesday, March 4th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Scholar Rock in a research note on Tuesday, April 21st. Five analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $56.00.

Insider Buying and Selling

In related news, insider Akshay Vaishnaw sold 12,246 shares of the stock in a transaction dated Thursday, April 16th. The shares were sold at an average price of $49.57, for a total transaction of $607,034.22. Following the sale, the insider directly owned 630,542 shares of the company's stock, valued at approximately $31,255,966.94. This represents a 1.91% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Keith Woods sold 10,220 shares of the stock in a transaction dated Thursday, April 16th. The shares were sold at an average price of $49.57, for a total transaction of $506,605.40. Following the sale, the chief operating officer directly owned 620,055 shares in the company, valued at $30,736,126.35. This trade represents a 1.62% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 102,736 shares of company stock worth $4,977,900 over the last 90 days. Corporate insiders own 13.30% of the company's stock.

Institutional Trading of Scholar Rock

Several institutional investors have recently bought and sold shares of the company. Invesco Ltd. grew its position in Scholar Rock by 21.0% during the 4th quarter. Invesco Ltd. now owns 82,462 shares of the company's stock valued at $3,632,000 after purchasing an additional 14,291 shares during the last quarter. Mercer Global Advisors Inc. ADV purchased a new stake in Scholar Rock during the 4th quarter valued at about $308,000. Mackenzie Financial Corp purchased a new stake in Scholar Rock during the 4th quarter valued at about $221,000. Empowered Funds LLC purchased a new stake in Scholar Rock during the 4th quarter valued at about $114,000. Finally, KVP Capital Advisors LP purchased a new stake in Scholar Rock during the 4th quarter valued at about $1,982,000. 91.08% of the stock is owned by hedge funds and other institutional investors.

Scholar Rock Company Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company's research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock's approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company's lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.